BCL-2, topoisomerase IIα, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy

Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings

(2013) T. M. A. Abdel-Fatah et al.   ANNALS OF ONCOLOGY

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

(2013) H. Masuda et al.   CLINICAL CANCER RESEARCH

Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: a systematic review and meta-analysis

(2013) Dong Yang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

Prognostic influence of BCL2 expression in breast cancer

(2012) Ki-Tae Hwang et al.   INTERNATIONAL JOURNAL OF CANCER

Microvessel Density and Status of p53 Protein as Potential Prognostic Factors for Adjuvant Anthracycline Chemotherapy in Retrospective Analysis of Early Breast Cancer Patients Group

(2012) Beata Biesaga et al.   PATHOLOGY & ONCOLOGY RESEARCH

Oncogenes in Cell Survival and Cell Death

(2012) J. Shortt et al.   Cold Spring Harbor Perspectives in Biology

Prognostic potential of topoisomerase IIα and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy

(2011) Beata Biesaga et al.   BREAST

Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between “triple-negative” and non–“triple-negative” tumors

(2011) Kareem Tawfik et al.   HUMAN PATHOLOGY

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy

(2010) C. Dumontet et al.   CLINICAL CANCER RESEARCH

Prognostic Value of p53 and bcl-2 Expression in Patients Treated with Breast Conservative Therapy

(2010) Kyubo Kim et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer

(2009) Grace M Callagy et al.   BMC CANCER

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY